文献速递核素与放射性配体治疗放射性药物与辐射防护

晚期神经内分泌肿瘤患者接受肽受体放射性配体治疗后的重度血小板减少症

Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy.
PubMed 文献 · Clin Nucl Med · 2022-01-01

本文报告3例转移性胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATATE肽受体放射性配体治疗(PRRT)后出现重度持续性血小板减少,骨髓活检均证实广泛肿瘤浸润;作者指出已知骨转移并非PRRT禁忌证,但血小板减少可能是肿瘤进展的表现,在决定是否继续治疗时应予以考虑。

要点

  • 3例转移性胃肠胰神经内分泌肿瘤患者接受1至4剂177Lu-DOTATATE 7.4 GBq(200 mCi)后出现3级难治性血小板减少。
  • 3例均合并骨转移,其中2例基线即有1级血小板减少,骨髓活检均示广泛肿瘤浸润。
  • 作者认为已知骨转移不是PRRT禁忌证,但血小板减少可能是肿瘤进展的表现,决定是否继续治疗时应予考虑。

核心结论

  • PRRT后重度难治性血小板减少罕见,可能由多种已知原因引起,包括辐射诱导的骨髓毒性、骨髓增生异常综合征和肿瘤骨髓浸润。
  • 本文报告3例血小板减少与持续或进展性骨髓转移相关。
  • 作者认为已知骨转移不是PRRT的禁忌证,但血小板减少可能是肿瘤进展的表现,在决定是否继续治疗时应予以考虑。

研究设计与样本

  • 本文为病例报告,回顾性识别3例接受PRRT后因持续性重度血小板减少而进行骨髓活检的转移性胃肠胰神经内分泌肿瘤患者。
  • 评估内容包括肿瘤特征(含免疫组化标志物)、治疗方式和临床结局。

主要发现

  • 3例患者均为转移性神经内分泌肿瘤,既往多线治疗进展,接受1至4剂177Lu-DOTATATE 7.4 GBq(200 mCi)后出现3级(25,000至50,000/μL)难治性血小板减少。
  • 3例均合并骨转移,其中2例基线有1级血小板减少。
  • 3例骨髓活检均证实广泛肿瘤浸润。

临床怎么用

  • 作者认为已知骨转移不是PRRT的禁忌证。
  • 作者认为血小板减少可能是肿瘤进展的表现,在决定是否继续治疗时应予以考虑。

局限性

  • 本文为3例病例报告,患者为回顾性识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peptide receptor radioligand therapy (PRRT) was Food and Drug Administration approved in 2018 for the treatment of unresectable somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs) and provides an important option for patients with advanced disease. A known adverse effect of this treatment is hematologic toxicity, although usually transient. We present 3 patients with metastatic gastroenteropancreatic NETs treated with PRRT who were evaluated for severe persistent thrombocytopenia. METHODS: Three patients who commenced therapy with PRRT were known to proceed to a bone marrow (BM) biopsy for persistent severe thrombocytopenia and were included in this study. These patients were identified retrospectively and evaluated for their tumor properties, including immunohistochemical markers, treatment modalities, and clinical outcomes. RESULTS: All 3 patients had metastatic NETs that progressed on prior lines of therapy and were treated with 1 to 4 doses of 177Lu-DOTATATE 7.4 GBq (200 mCi) before developing grade 3 (25,000 to 50,000/μL) refractory thrombocytopenia. All patients had concurrent bone metastases, and 2 of the 3 had baseline grade 1 thrombocytopenia. In all 3 cases, BM biopsy documented widespread tumor infiltration. CONCLUSIONS: Severe refractory thrombocytopenia after PRRT is rare and may result from numerous known causes, including radiation-induced myelotoxicity, myelodysplastic syndrome, and tumor BM infiltration. We present 3 cases of thrombocytopenia related to persistent or progressive BM metastasis. Although known bone metastasis is not a contraindication to PRRT, thrombocytopenia may be a manifestation of tumor progression and should be considered when making decisions about continuation of therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Naveed Ahmad JA, Schroeder BB, Ruhoy SM, et al. Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy. Clin Nucl Med. 2022. PMID: 35307721. doi:10.1097/RLU.0000000000004130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。